HR
HTGM

Hayden Royal’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Hayden Royal’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-67
Closed -$8K – 251
2019
Q3 		$8K Buy
+67
New +$13.5K 0.01% 164

Other funds holding HTGM

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HWM
HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Hayden Royal's HTGM Position: Q4 2019 in Review

Hayden Royal sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2019, closing a stake of 67 shares — an estimated $8K sold.

Hayden Royal first reported a position in HTGM in Q3 2019 and held it in 1 quarter. The position peaked at $8K in Q3 2019. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

  • Hayden Royal reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Hayden Royal sold 67 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2019, an estimated $8K.
  • Hayden Royal first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Hayden Royal's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $8K in Q3 2019.
  • 27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2019.

Based on Hayden Royal's 13F filing for Q4 2019, filed 24 Feb 2020.